Kellton Tech to issue $10 million in FCCBs at ₹106 floor price; bond issuance opening on May 16
Kellton Tech Solutions has announced the issuance of Foreign Currency Convertible Bonds (FCCBs) worth USD 10 million, with a floor price set at ₹ 106 per equity share. The announcement comes ahead of the bond issuance opening on May 16, 2025, following board approval granted earlier this week.
In a regulatory filing, the company disclosed that the Security Issuance Committee, following the board meeting held on May 14, 2025, has been authorised to manage the entire FCCB issuance process.
The FCCBs will be issued internationally and are structured as 6.5 percent senior unsecured bonds with a maturity period extending to 10 years and 1 month from the date of full payment. The floor price for conversion has been determined in accordance with the FCCB Scheme, using May 14, 2025, as the relevant date for pricing calculations.
At a conversion rate of INR 85.3 per USD, the bond issuance translates to approximately ₹ 85.3 crore, which upon full conversion, would result in the allotment of nearly 80.47 lakh equity shares of ₹ 5 each. The company expects to complete the allotment of FCCBs within 30 days from the issue's closing date.
Notably, the filing also clarified that there have been no defaults in the company's past FCCB obligations, and there is no proposal to issue preferential or bonus shares alongside this offering. The move underscores Kellton Tech's focus on shoring up its capital structure to support future growth through diversified funding channels.
The market responded positively to the development. On Thursday, May 15, Kellton Tech's shares rose as much as 1.3 percent in intra-day trade to touch ₹ 117.10. While still over 36 percent below its 52-week high of ₹ 184.30 recorded in July 2024, the stock has shown signs of recovery. It has gained nearly 38 percent from its 52-week low of ₹ 85, hit in June 2024.
Over the past year, the stock has appreciated 20 percent. Notably, after enduring four straight months of losses, the stock has rebounded in May with a near 9 percent gain so far. It had declined 0.5 percent in April, 1.4 percent in March, 25.4 percent in February, and 3 percent in January.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
32 minutes ago
- Economic Times
Motilal Oswal initiates coverage on Laxmi Dental with Rs 540 target; stock zooms 10%
Considering the supportive industry trend, domestic brokerage firm Motilal Oswal has initiated coverage on Laxmi Dental, with a 'buy' rating and a target price of Rs 540 for the stock, an upside potential of 26% from its previous closing. ADVERTISEMENT This was followed by a 9.6% surge in the shares of Laxmi Dental, taking the price to its day's high of Rs 469 on the BSE. 'Considering the supportive industry trend and Laxmiden's potential for sustained growth, we assign a 43x 12M forward earnings multiple to arrive at our TP of Rs 540,' said Motilal Oswal in its note, highlighting that the company has no direct competitors in the listed space. The note stated that the company's select focus on therapies, a customized and scalable business model, and strong growth momentum have led the brokerage firm to assign a similar multiple to Laxmi Dental. Laxmi Dental is the second-largest player in India's domestic lab segment, serving over 22,000 dental clinics and dentists across 320 cities. It exports to more than 90 countries and operates the largest export lab business. Industry growth is supported by rising digital dentistry adoption, a shift to premium metal-free products, and growing outsourcing of US lab work to is also a preferred partner for Heartland, one of the largest US-based Dental Service Organizations (DSOs), and was among the first to launch branded zirconia crowns under the 'Illusion Zirconia' brand. ADVERTISEMENT The company is also a leading importer of IOS scanners in India, with over 600 devices deployed under the iScanPro brand. Its legacy lab business, which contributes 62% of total sales, grew at a 15% CAGR to reach Rs 1,500 crore between FY22 and FY25. Domestic lab sales grew at 13% CAGR to Rs 871 crore in FY25, while its international labs business reported 17% CAGR growth, reaching Rs 607 Laxmiden's labs business is projected to grow at 21% CAGR over FY25–27, reaching Rs 2,200 crore. ADVERTISEMENT Also read: Jane Street complies with Sebi, deposits Rs 4,843 crore in escrow accountFurther, the global clear aligner market is projected to grow at a 15% CAGR to reach USD 55 billion by 2030. Laxmiden, the only fully integrated aligner player in India, manufactures and sells customized aligners via its Bizdent (B2C) and Vedia (B2B) units. Its 'Illusion Aligners' brand was the first Indian brand to secure US FDA 510(k) clearance in CY21. The company expects its aligner business to grow at a 33% CAGR over FY25–27, reaching ₹1,400 crore in revenue by FY27. ADVERTISEMENT The global pediatric crown market is expected to grow at a 7.5% CAGR, reaching USD 3.5 billion by 2030. Laxmiden, the only Indian manufacturer of Silver Diamine Fluoride (SDF), cleared by USFDA, also markets its BiofixTM crowns in India. The pediatric segment is expected to deliver 31% CAGR over FY25–27, with revenue reaching ₹449 crore and a projected PAT of ₹95 crore in healthcare services sector is evolving, with business models focusing on specific therapies and subsequently creating a comprehensive ecosystem. The customized service aspect not only adds value for patients but also benefits companies, establishing a strong competitive advantage for sustainable growth. ADVERTISEMENT Laxmi Dental has developed a comprehensive framework to bridge the gap in dentistry, effectively addressing the needs of patients across all age groups while enhancing the efficiency of dental practitioners. The adoption of technology has resulted in improved prospects in the international market. By utilizing celebrity brand endorsements as part of its marketing strategy, the company has also expanded its offerings in the aligner commenting on the risks, the brokerage firm noted that Laxmi Dental's growth may be impacted by delays in receiving approvals to launch or register products in international markets. Slower industry-wide adoption of new technologies could weaken its competitive a slower expansion of dentist coverage could limit growth in its domestic lab business and the emergence of alternative dental solutions replacing crowns or bridges may reduce overall demand and affect business prospects. Also read: Ola Electric Q1 Results: Net loss widens 23% YoY to Rs 428 crore, revenue drops 50% (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
Time of India
35 minutes ago
- Time of India
Motilal Oswal initiates coverage on Laxmi Dental with Rs 540 target; stock zooms 10%
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Considering the supportive industry trend, domestic brokerage firm Motilal Oswal has initiated coverage on Laxmi Dental , with a 'buy' rating and a target price of Rs 540 for the stock, an upside potential of 26% from its previous was followed by a 9.6% surge in the shares of Laxmi Dental, taking the price to its day's high of Rs 469 on the BSE.'Considering the supportive industry trend and Laxmiden's potential for sustained growth, we assign a 43x 12M forward earnings multiple to arrive at our TP of Rs 540,' said Motilal Oswal in its note, highlighting that the company has no direct competitors in the listed note stated that the company's select focus on therapies, a customized and scalable business model, and strong growth momentum have led the brokerage firm to assign a similar multiple to Laxmi Dental is the second-largest player in India's domestic lab segment, serving over 22,000 dental clinics and dentists across 320 cities. It exports to more than 90 countries and operates the largest export lab business. Industry growth is supported by rising digital dentistry adoption, a shift to premium metal-free products, and growing outsourcing of US lab work to is also a preferred partner for Heartland, one of the largest US-based Dental Service Organizations (DSOs), and was among the first to launch branded zirconia crowns under the 'Illusion Zirconia' company is also a leading importer of IOS scanners in India, with over 600 devices deployed under the iScanPro brand. Its legacy lab business, which contributes 62% of total sales, grew at a 15% CAGR to reach Rs 1,500 crore between FY22 and FY25. Domestic lab sales grew at 13% CAGR to Rs 871 crore in FY25, while its international labs business reported 17% CAGR growth, reaching Rs 607 Laxmiden's labs business is projected to grow at 21% CAGR over FY25–27, reaching Rs 2,200 read: Jane Street complies with Sebi, deposits Rs 4,843 crore in escrow account Further, the global clear aligner market is projected to grow at a 15% CAGR to reach USD 55 billion by 2030. Laxmiden, the only fully integrated aligner player in India, manufactures and sells customized aligners via its Bizdent (B2C) and Vedia (B2B) units. Its 'Illusion Aligners' brand was the first Indian brand to secure US FDA 510(k) clearance in CY21. The company expects its aligner business to grow at a 33% CAGR over FY25–27, reaching ₹1,400 crore in revenue by global pediatric crown market is expected to grow at a 7.5% CAGR, reaching USD 3.5 billion by 2030. Laxmiden, the only Indian manufacturer of Silver Diamine Fluoride (SDF), cleared by USFDA, also markets its BiofixTM crowns in India. The pediatric segment is expected to deliver 31% CAGR over FY25–27, with revenue reaching ₹449 crore and a projected PAT of ₹95 crore in healthcare services sector is evolving, with business models focusing on specific therapies and subsequently creating a comprehensive ecosystem. The customized service aspect not only adds value for patients but also benefits companies, establishing a strong competitive advantage for sustainable Dental has developed a comprehensive framework to bridge the gap in dentistry, effectively addressing the needs of patients across all age groups while enhancing the efficiency of dental adoption of technology has resulted in improved prospects in the international market. By utilizing celebrity brand endorsements as part of its marketing strategy, the company has also expanded its offerings in the aligner commenting on the risks, the brokerage firm noted that Laxmi Dental's growth may be impacted by delays in receiving approvals to launch or register products in international markets. Slower industry-wide adoption of new technologies could weaken its competitive a slower expansion of dentist coverage could limit growth in its domestic lab business and the emergence of alternative dental solutions replacing crowns or bridges may reduce overall demand and affect business read: Ola Electric Q1 Results: Net loss widens 23% YoY to Rs 428 crore, revenue drops 50% (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
The Print
an hour ago
- The Print
Indian team in Washington; trade talks to begin Monday: Official
Chief negotiator of India and special secretary in the department of commerce Rajesh Agrawal will join the team on Wednesday. New Delhi, Jul 14 (PTI) An Indian commerce ministry team has reached Washington for another round of talks on the proposed bilateral trade agreement (BTA), which will begin on Monday, an official said. India's deputy chief negotiator for the proposed BTA has reached Washington for the talks on the first phase of the BTA, the official said. The visit assumes significance as both sides have to iron out issues in sectors, like agriculture and automobiles. It is also important as the US has further postponed the imposition of additional tariffs on several countries, including India, until August 1. Last week, an official has said that 'we are not differentiating between an interim or the first phase of the bilateral trade agreement. We are negotiating a complete deal. Whatever will be finished, we can package it as an interim deal and for the rest, talks will continue'. Earlier this month, the Indian team was in Washington for talks, with negotiations taking place from June 26 to July 2. The team has once again reached the US for negotiations. India has hardened its position on the US demand for duty concessions on agri and dairy products. New Delhi has, so far, not given any duty concessions to any of its trading partners in a free trade agreement in the dairy sector. India is seeking the removal of this additional tariff (26 per cent). It is also seeking the easing of tariffs on steel and aluminium (50 per cent) and the auto (25 per cent) sectors. Against these, India has reserved its right under the WTO (World Trade Organization) norms to impose retaliatory duties. US President Donald Trump announced heavy tariffs on a number of countries, including India, on April 2. However, it was soon postponed for 90 days until July 9 and later to August 1. From July 7, the Trump administration has issued tariff letters to a number of its trading partners, including Bangladesh, Indonesia, Japan, South Korea, Malaysia, Thailand, South Africa, Bosnia and Herzegovina, Cambodia, Kazakhstan, Laos, Serbia, and Tunisia. The US wants duty concessions on certain industrial goods, automobiles, especially electric vehicles, wines, petrochemical products, and agri goods, like dairy items, apples, tree nuts, and genetically modified crops. On the other hand, India is seeking duty concessions for labour-intensive sectors, such as textiles, gems and jewellery, leather goods, garments, plastics, chemicals, shrimp, oil seeds, grapes, and bananas in the proposed trade pact. The two countries are looking to conclude talks for the first tranche of the proposed bilateral trade agreement (BTA) by fall (September-October) this year. Before that, they are looking for an interim trade pact. India's merchandise exports to the US rose 21.78 per cent to USD 17.25 billion in April-May this fiscal year, while imports rose 25.8 per cent to USD 8.87 billion. PTI RR TRB TRB This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
